Mesoblast Limited (ASX:MSB) Insider Jane Bell Acquires 233,918 Shares

Mesoblast Limited (ASX:MSB) insider Jane Bell purchased 233,918 shares of the stock in a transaction that occurred on Friday, April 12th. The shares were acquired at an average cost of A$0.86 ($0.55) per share, for a total transaction of A$199,999.89 ($129,032.19).

Mesoblast Price Performance

The company has a debt-to-equity ratio of 23.98, a current ratio of 2.71 and a quick ratio of 1.82.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.